Dr Enoch Kariuki has been named as the new Chief Financial Officer at biopharma firm VelosBio, where he will assume responsibility for the company’s finance-related and investor relations functions.
He brings with him a wealth of knowledge built over a career in life sciences investment banking, venture capital, business development and healthcare strategy. In his most recent role prior to this appointment, Dr Kariuki helped lead the $151 million initial public offering for Synthorx as its Senior Vice President, Corporate Development, successfully selling the company to Sanofi for $2.5 billion.
Before that, he was Vice President at investment firm HIG Capital and has served on the boards of a number of life sciences companies. He has also completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol-Myers Squib.
“Enoch brings to VelosBio more than 10 years of experience leading high-performing teams in the private and public sectors,” remarked Dave Johnson, Chief Executive Officer at VelosBio. “He has a proven track record of success on both the operating and finance sides of our industry, and is precisely the type of high quality individual we are recruiting as we grow our company. He will be an invaluable asset to VelosBio and our leadership team as we advance our clinical pipeline focused on ROR1-directed therapeutics.”